FDA Grants Approval for Novavax COVID-19 Vaccine: What You Need to Know About Its Unique Restrictions

WASHINGTON (AP) — The FDA has finally approved Novavax’s COVID-19 vaccine, but with some notable restrictions. This vaccine is unique as it’s the only protein-based option available in the U.S.

Until now, Novavax held emergency authorization for anyone aged 12 and older. However, the full approval is now limited to adults 65 and older. It also includes those aged 12 to 64 who have certain health conditions that heighten their risk from COVID-19.

In contrast, vaccines from Pfizer and Moderna are fully licensed for all individuals aged 12 and up, with approvals extending to children as young as 6 months. This decision comes just as key advisers for the CDC are set to discuss whether COVID vaccinations should still be recommended universally or targeted to high-risk groups.

John C. Jacobs, Novavax’s CEO, welcomed the FDA’s approval. He pointed out that research shows older adults and those with pre-existing conditions are the most likely to seek seasonal vaccinations. “This is a significant step toward making our protein-based vaccine available to those who need it most,” he noted.

Interestingly, the FDA’s letter did not articulate why they imposed these restrictions. Some experts suggest this reflects ongoing skepticism about vaccines from certain political figures.

Novavax had previously demonstrated its vaccine’s safety and efficacy in a large clinical trial involving 30,000 participants. The FDA was expected to grant full approval without restrictions earlier this year. However, they requested Novavax to conduct additional trials after the approval, which is quite rare.

These further studies will look into potential links between the vaccine and certain heart conditions, among other requirements. There will also be an evaluation of the vaccine’s benefits for those aged 50 to 64 without health issues.

This cautious approach echoes wider trends in vaccine acceptance and skepticism. A recent Pew Research survey revealed that only about 60% of Americans plan to get the latest COVID-19 vaccine, highlighting ongoing public wariness.

The implications of these restrictions are significant. They may influence future vaccination campaigns and public trust in newer vaccine options.

For more insights on vaccination trends, you can refer to the CDC’s COVID-19 Vaccination page.

Source link

U.S. Food and Drug Administration, Immunizations, Medication, General news, AP Top News, Washington news, Moderna, Inc., Novavax, Inc., Health, Robert F. Kennedy Jr., John C. Jacobs, Clinical trials, COVID-19 pandemic, Pfizer Inc., Business, Washington News